← All companies

Science / Company profile

Relation Therapeutics

What Relation Therapeutics does

Relation Therapeutics is a privately held, London-headquartered technology-enabled biopharmaceutical company applying machine learning to human cellular data and pairing computation with experimental validation to support drug target discovery. Its core approach is described as a “Lab-in-the-Loop,” integrating single-cell multi-omics and functional assays with machine learning to identify and validate causal genes and refine target hypotheses, with the goal of improving the probability of success in drug discovery and development. (On the company’s website, the company characterizes its science as “causal biology” and a “Lab-in-the-Loop” that drives “cause to cure.”)

News

Company record

Jul 30, 2026 · Official · GlobeNewswireRelation Announces Expanded Collaboration with GSK

Relation announced an expanded strategic research collaboration with GSK focused on generating large-scale human cellular perturbation datasets and deploying them into models including MORGAN. The company stated it may receive up to $110 million in upfront and success-based milestone payments.

Jul 30, 2026 · Official · GlobeNewswireRelation unveils MORGAN, the next-generation model of cellular biology

Relation unveiled MORGAN, a cellular foundation model intended to predict cellular responses to genetic and pharmacological interventions, built from large-scale, high-resolution multi-omic perturbation data and paired with an automated, high-throughput experimental data generation approach.

Dec 09, 2025 · Official · GlobeNewswireRelation announces further $26 million investment

Relation announced a further $26 million investment from existing investors NVentures and deeptech investors DCVC and Magnetic Ventures.

Dec 10, 2024 · Official · GlobeNewswireRelation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

Relation announced two multi-program strategic collaborations with GSK focused on identifying and validating novel therapeutic targets for fibrotic diseases and osteoarthritis. The company stated the collaborations include $45 million upfront (including $15 million equity investment) and eligibility for up to $63 million in success-based payments, plus milestone payments averaging $200 million per target and tiered royalties on net sales.

Mar 14, 2024 · Official · GlobeNewswireRelation Therapeutics secures $35 million of new seed financing led by DCVC and co-lead NVentures, NVIDIA’s venture arm

Relation announced a $35 million new seed financing led by DCVC and co-led by NVentures, with participation from Magnetic Ventures, Khosla Ventures, Abcam founder Jonathan Milner, ARK Invest, and Deerfield Management Company. Relation stated the round brought total seed fundraise to $60 million.

Feb 22, 2023 · Official · Business WireRelation Therapeutics announces launch of flagship integrated wet–dry laboratory at the heart of London’s Knowledge Quarter

Relation announced the opening of a flagship integrated wet–dry laboratory in London’s Knowledge Quarter, describing the lab’s role in combining functional genomics and computational/machine-learning capabilities as part of its Lab-in-the-Loop approach. The company also described Osteoporosis as its first indication and referenced its indication-selection engine “Selectomatic.”

Source map · 2 recurring channels · 17 references

Still resolving: Newsroom · Official X

Funding

Latest disclosed valuationNot disclosed
Tracked capital$101M5 sourced rounds
DateRoundRaisedValuationLead / investorsEvidence
Dec 09, 2025investment (existing investors)$26M
Not attributed
+3 investors
Dec 10, 2024Strategic equity investment (from collaboration upfront)$15M
Jul 01, 2022seed (initial)
Not attributed
+1 investor

What it builds

Lab-in-the-Loop platform

Relation describes a closed-loop system that integrates patient-derived multi-omic data, machine learning, and proprietary experimental systems to uncover causal biology and iteratively refine target hypotheses for drug discovery and development.

source ↗
Osteomics

Relation’s proprietary functional single-cell bone atlas, described as a clinical observational study using patient-derived samples with single-cell and spatial omics plus other profiling to uncover bone homeostasis biology and support discovery of therapeutic targets and biomarkers.

source ↗
Selectomatic

Relation describes “Selectomatic” as a proprietary machine-learning engine for indication selection, used to recommend indications where the company’s integrated platform can develop transformational therapeutics.

source ↗
MORGAN (Multi-Omic Regulatory Genomics using Artificial Neural Networks)

Relation describes MORGAN as its cellular foundation model, intended to predict how human cells respond to genetic and pharmacological interventions, trained on large-scale multi-omic perturbation data, and deployed as general-purpose or tissue-/disease-area-specific models.

source ↗

Key metrics

Milestones & partnerships